12.17
price down icon0.65%   -0.08
after-market After Hours: 12.04 -0.13 -1.07%
loading
Intellia Therapeutics Inc stock is traded at $12.17, with a volume of 4.39M. It is down -0.65% in the last 24 hours and up +22.43% over the past month. Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
See More
Previous Close:
$12.25
Open:
$12.61
24h Volume:
4.39M
Relative Volume:
1.52
Market Cap:
$1.24B
Revenue:
$45.97M
Net Income/Loss:
$-508.80M
P/E Ratio:
-2.2208
EPS:
-5.48
Net Cash Flow:
$-382.65M
1W Performance:
+13.74%
1M Performance:
+22.43%
6M Performance:
-48.45%
1Y Performance:
-54.72%
1-Day Range:
Value
$11.93
$12.63
1-Week Range:
Value
$10.89
$12.84
52-Week Range:
Value
$8.96
$34.87

Intellia Therapeutics Inc Stock (NTLA) Company Profile

Name
Name
Intellia Therapeutics Inc
Name
Phone
857-285-6200
Name
Address
40 ERIE STREET, CAMBRIDGE, MA
Name
Employee
598
Name
Twitter
@intelliatweets
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
NTLA's Discussions on Twitter

Compare NTLA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
NTLA
Intellia Therapeutics Inc
12.17 1.24B 45.97M -508.80M -382.65M -5.48
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.24 124.35B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
700.33 76.56B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
644.48 39.16B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
250.59 32.44B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
BNTX
Biontech Se Adr
120.01 28.77B 3.30B -501.07M 1.03B -2.1146

Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-27-25 Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-23-24 Downgrade Goldman Buy → Neutral
Feb-15-24 Initiated Wolfe Research Peer Perform
Apr-13-23 Initiated Canaccord Genuity Buy
Mar-21-23 Initiated Bernstein Outperform
Mar-14-23 Upgrade BMO Capital Markets Market Perform → Outperform
Feb-01-23 Initiated Cantor Fitzgerald Overweight
Jan-24-23 Upgrade Citigroup Sell → Neutral
Jan-19-23 Downgrade JMP Securities Mkt Outperform → Mkt Perform
Oct-11-22 Initiated Morgan Stanley Overweight
Sep-21-22 Initiated JP Morgan Overweight
Sep-01-22 Initiated Citigroup Sell
Jun-17-22 Initiated BMO Capital Markets Market Perform
Jun-16-22 Initiated BofA Securities Buy
Apr-28-22 Initiated Credit Suisse Outperform
Feb-18-22 Initiated William Blair Outperform
Feb-07-22 Upgrade Oppenheimer Perform → Outperform
Jan-31-22 Initiated Cowen Outperform
Jan-07-22 Initiated Piper Sandler Overweight
Oct-05-21 Initiated Guggenheim Buy
Sep-24-21 Initiated Stifel Buy
Jun-28-21 Reiterated H.C. Wainwright Buy
Jun-11-21 Initiated H.C. Wainwright Buy
May-07-21 Upgrade ROTH Capital Neutral → Buy
May-04-21 Initiated RBC Capital Mkts Outperform
Mar-04-21 Initiated JMP Securities Mkt Outperform
Dec-22-20 Downgrade Robert W. Baird Outperform → Neutral
Oct-27-20 Initiated Truist Buy
Oct-14-20 Initiated Wells Fargo Overweight
Sep-18-20 Initiated Goldman Buy
Feb-28-20 Upgrade Oppenheimer Perform → Outperform
Feb-14-20 Downgrade Wedbush Outperform → Neutral
Nov-01-19 Upgrade Raymond James Mkt Perform → Outperform
Jul-09-19 Initiated Robert W. Baird Outperform
Jun-10-19 Initiated ROTH Capital Neutral
May-03-19 Upgrade Wedbush Neutral → Outperform
Apr-12-19 Initiated Evercore ISI Outperform
Nov-02-18 Downgrade Wedbush Outperform → Neutral
Oct-29-18 Initiated Credit Suisse Neutral
Sep-21-18 Initiated Raymond James Mkt Perform
May-15-18 Upgrade Chardan Capital Markets Neutral → Buy
Mar-08-18 Initiated JMP Securities Mkt Outperform
Nov-01-17 Reiterated Jefferies Buy
Jun-22-17 Resumed Jefferies Buy
Mar-28-17 Initiated Chardan Capital Markets Buy
Aug-05-16 Upgrade Jefferies Hold → Buy
View All

Intellia Therapeutics Inc Stock (NTLA) Latest News

pulisher
Feb 21, 2025

ROSEN, LEADING INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure ... - The Bakersfield Californian

Feb 21, 2025
pulisher
Feb 21, 2025

ROSEN, LEADING INVESTOR COUNSEL, Encourages Intellia - GlobeNewswire

Feb 21, 2025
pulisher
Feb 21, 2025

ROSEN, LEADING INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLA - GlobeNewswire Inc.

Feb 21, 2025
pulisher
Feb 21, 2025

Intellia signs major lease for expansion, amends existing lease - Investing.com India

Feb 21, 2025
pulisher
Feb 21, 2025

Intellia Therapeutics, Inc. Sued for Securities Law - GlobeNewswire

Feb 21, 2025
pulisher
Feb 20, 2025

NTLA Investors are Suing Intellia Therapeutics, Inc.; Contact Robbins LLP for More Information - GlobeNewswire

Feb 20, 2025
pulisher
Feb 20, 2025

Faruqi & Faruqi Reminds Intellia Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025NTLA - PR Newswire

Feb 20, 2025
pulisher
Feb 20, 2025

Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - Yahoo Finance

Feb 20, 2025
pulisher
Feb 20, 2025

Intellia Therapeutics (NTLA) Stock Jumps 6.5%: Will It Continue to Soar? - Yahoo Canada Finance

Feb 20, 2025
pulisher
Feb 20, 2025

Intellia Therapeutics to Hold Conference Call to Discuss - GlobeNewswire

Feb 20, 2025
pulisher
Feb 20, 2025

Gene Editing Pioneer Intellia Sets Critical Q4 Earnings Review: Will CRISPR Progress Match Expectations? - StockTitan

Feb 20, 2025
pulisher
Feb 20, 2025

The Gross Law Firm Notifies Shareholders of Intellia Therapeutics, Inc.(NTLA) of a Class Action Lawsuit and an Upcoming Deadline - PR Newswire

Feb 20, 2025
pulisher
Feb 20, 2025

Intellia Therapeutics (NTLA) Expected to Announce Earnings on Thursday - MarketBeat

Feb 20, 2025
pulisher
Feb 19, 2025

NTLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire

Feb 19, 2025
pulisher
Feb 19, 2025

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics - GlobeNewswire

Feb 19, 2025
pulisher
Feb 19, 2025

Chevy Chase Trust Holdings LLC Sells 522,712 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat

Feb 19, 2025
pulisher
Feb 18, 2025

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc of Class Action Lawsuit and Upcoming DeadlinesNTLA - PR Newswire

Feb 18, 2025
pulisher
Feb 18, 2025

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics - TradingView

Feb 18, 2025
pulisher
Feb 18, 2025

Shareholders of Intellia Therapeutics, Inc. Should Contact - GlobeNewswire

Feb 18, 2025
pulisher
Feb 18, 2025

Shareholders of Intellia Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights – NTLA - TradingView

Feb 18, 2025
pulisher
Feb 18, 2025

How to Take Advantage of moves in (NTLA) - Stock Traders Daily

Feb 18, 2025
pulisher
Feb 18, 2025

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Intellia - GlobeNewswire

Feb 18, 2025
pulisher
Feb 18, 2025

INTELLIA THERAPEUTICS, INC. (NASDAQ: NTLA) DEADLINE ALERT: - GlobeNewswire

Feb 18, 2025
pulisher
Feb 18, 2025

Intellia Therapeutics, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before April 14, 2025 to Discuss Your RightsNTLA - Morningstar

Feb 18, 2025
pulisher
Feb 17, 2025

NTLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Intellia Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Business Wire

Feb 17, 2025
pulisher
Feb 16, 2025

2025-02-16 | INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics | NDAQ:NTLA | Press Release - Stockhouse Publishing

Feb 16, 2025
pulisher
Feb 16, 2025

Sumitomo Mitsui Trust Group Inc. Sells 156,736 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat

Feb 16, 2025
pulisher
Feb 16, 2025

ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages - GlobeNewswire

Feb 16, 2025
pulisher
Feb 15, 2025

Intellia Therapeutics (NASDAQ:NTLA) Sets New 1-Year LowWhat's Next? - MarketBeat

Feb 15, 2025
pulisher
Feb 14, 2025

INTELLIA ALERT: Bragar Eagel & Squire, P.C. Announces that - GlobeNewswire

Feb 14, 2025
pulisher
Feb 14, 2025

NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit - PR Newswire

Feb 14, 2025
pulisher
Feb 14, 2025

Intellia Therapeutics (NTLA): Among The Small–Cap Stocks Insiders Are Selling Recently - Insider Monkey

Feb 14, 2025
pulisher
Feb 14, 2025

Does Intellia Therapeutics (NTLA) Have the Potential to Rally 422.41% as Wall Street Analysts Expect? - Yahoo Finance

Feb 14, 2025
pulisher
Feb 14, 2025

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Intellia Therapeutics, Inc.(NTLA) Shareholders - PR Newswire

Feb 14, 2025
pulisher
Feb 14, 2025

Intellia Therapeutics (NASDAQ:NTLA) Sets New 12-Month LowShould You Sell? - MarketBeat

Feb 14, 2025
pulisher
Feb 14, 2025

Intellia Therapeutics, Inc. Shareholder Notice: Shareholder - GlobeNewswire

Feb 14, 2025
pulisher
Feb 13, 2025

Intellia Therapeutics, Inc. Shareholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Against NTLA - GlobeNewswire

Feb 13, 2025
pulisher
Feb 13, 2025

Rosen Law Firm Urges Intellia Therapeutics, Inc. (NASDAQ: NTLA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights - The Bakersfield Californian

Feb 13, 2025
pulisher
Feb 13, 2025

NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire

Feb 13, 2025
pulisher
Feb 12, 2025

Investor Alert: Robbins LLP Informs Stockholders of the Intellia Therapeutics, Inc. Class Action - PR Newswire

Feb 12, 2025
pulisher
Feb 12, 2025

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics - GlobeNewswire

Feb 12, 2025
pulisher
Feb 12, 2025

INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire

Feb 12, 2025
pulisher
Feb 12, 2025

INTELLIA THERAPEUTICS, INC. (NASDAQ: NTLA) INVESTOR ALERT: - GlobeNewswire

Feb 12, 2025
pulisher
Feb 12, 2025

INTELLIA THERAPEUTICS, INC. (NASDAQ: NTLA) INVESTOR ALERT: Investors With Large Losses in - The Bakersfield Californian

Feb 12, 2025
pulisher
Feb 12, 2025

NTLA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Intellia Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Feb 12, 2025
pulisher
Feb 11, 2025

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors - GlobeNewswire

Feb 11, 2025

Intellia Therapeutics Inc Stock (NTLA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$33.42
price up icon 0.27%
$81.06
price down icon 3.05%
$361.10
price down icon 1.70%
$22.12
price down icon 4.08%
biotechnology ONC
$255.37
price up icon 4.57%
$120.01
price up icon 1.81%
Cap:     |  Volume (24h):